Transgenomic (NASDAQ:PRPO) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

Shares of Transgenomic (NASDAQ:PRPO) traded down $0.01 during mid-day trading on Friday, hitting $1.29. 22,359 shares of the stock traded hands, compared to its average volume of 58,755. Transgenomic has a 1 year low of $1.18 and a 1 year high of $47.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.07 and a current ratio of 0.08.

WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at

About Transgenomic

Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Transgenomic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgenomic Inc. and related companies with's FREE daily email newsletter.